TORONTO, Oct. 1 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical
company dedicated to the development and commercialization of cancer
therapies, announced today that Dr. Alan M. Ezrin, President and Chief
Executive Officer of the Company, will present a corporate update at
BioContact Québec 2008, which is being held in Québec City from October 1st -
3rd at the Château Frontenac. Dr. Ezrin will provide an update on the
Company's ongoing Phase III trial of Neuradiab(TM), a treatment for newly
diagnosed glioblastoma multiforme (GBM), and outline its business development
plans for 2009. The presentation will take place on Thursday, October 2nd at
4:00pm ET in the Laval Room and Dr. Ezrin will be available for questions
following his presentation.
Neuradiab is a monoclonal antibody, conjugated to radioactive iodine,
used to treat glioblastoma multiforme (GBM), the most common and most advanced
form of brain cancer. Neuradiab delivers tumor-killing radiation specifically
to residual brain tumor cells after surgery, with minimal impact on normal
brain tissue. During the course of development at Duke University, over US$60
million in research grants and related support has produced a series of Phase
I and Phase II clinical trials on Neuradiab and other closely related
technologies. Approximately 200 brain cancer patients, including over 160 with
GBM, have been treated with the Neuradiab therapy regimen, and survival
benefits have significantly exceeded historical controls in each completed
trial. Neuradiab has been formerly referred to in literature as 131-I
anti-tenascin monoclonal antibody 81c6.
Each year up to 30,000 new cases of GBM are diagnosed in the world's
seven largest healthcare markets. The current standard of care for GBM
patients is surgical resection followed by radiation and temozolomide. GBM
tumors typically have infiltrating edges that are very difficult to completely
remove with surgery. The Neuradiab therapy is delivered directly into the
surgical resection cavity in a separate procedure after the initial surgery.
Neuradiab delivers a concentrated level of radiation specifically to the
remaining cancer cells by targeting tenascin. Tenascin is a protein
over-expressed in 99% of GBM cells but absent from normal brain cells.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. Prior to the Company's inception, over
US$60 million in grants and related support had driven research and
development of the licensed treatment, which has been delivered to over 200
patients with promising results in Phase I and Phase II clinical trials at
Duke University. Bradmer has initiated enrollment in a Phase III multi-center
clinical trial of the licensed treatment. Neuradiab has been granted Orphan
Drug Status by both the U.S. Food and Drug Administration and the European
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc.: Mr. Brian
Brohman, Chief Financial Officer, Phone: (502) 657-6038, Fax: (502) 657-6039,
E-mail: email@example.com, Internet: www.bradmerpharma.com; Investor
Relations: Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: firstname.lastname@example.org